ArticleBrain and behavior2026
Comparing the Impact of Tetrahydrocannabinol on 30-Day Readmission Rates and Hospital Length of Stay in Patients With Depression.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDelta-9-tetrahydrocannabinol (THC), the psychoactive constituent of cannabis, continues to be critically evaluated for its potential therapeutic efficacy and associated safety concerns in major depressive disorder (MDD). Length of stay and readmission rates are key indicators of treatment response and prognosis. With rising cannabis use, understanding the effects of THC is essential. The objective of this study is to evaluate THC's impact on 30-day readmission and length of stay among inpatient MDD individuals at an academic hospital.
methodsA single-center retrospective chart review evaluated adult patients admitted for MDD between August 2018 and May 2025. Patients were categorized by positive or negative THC urine drug screen on admission. The primary outcomes were 30-day psychiatric readmission and hospital length of stay. Unadjusted and adjusted analyses were performed. Logistic regression was used to evaluate 30-day readmission, and multiple linear regression was used to evaluate length of stay. Adjusted models included age, gender at birth, psychiatric comorbidities, and polysubstance use.
resultsAmong 743 cases, 211 (28.4%) were THC positive. A THC-positive urine drug screen was not independently associated with 30-day psychiatric readmission (adjusted odds ratio [OR]: 0.821; 95% CI 0.319-2.115; p = 0.683) or difference in hospital length of stay (mean difference -0.242 days; 95% CI -0.983 to 0.499; p = 0.521). Older age was associated with longer length of stay, while female gender at birth was associated with shorter length of stay. DISCUSSION AND
conclusionsTHC-positive urine drug screens were not independently associated with 30-day psychiatric readmission or differences in hospital length of stay among patients hospitalized for MDD. Larger studies are needed to further evaluate the relationship between cannabis use and psychiatric hospitalization outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.